Related by context. All words. (Click for frequent words.) 80 undergoing percutaneous coronary 77 underwent percutaneous coronary 74 elective percutaneous coronary 72 primary percutaneous coronary 70 patients undergoing percutaneous 68 PCI percutaneous coronary 68 PLX STROKE targeting 64 dyslipidemia hypertension diabetes 64 undergoing coronary angiography 63 non valvular atrial 63 deep venous thromboses 62 noninvasive outpatient 61 deCODE AF TM 61 venous thromboembolic disease 61 percutaneous transluminal coronary angioplasty 61 stage IIIb IV 61 Carotid Revascularization Endarterectomy vs. 61 angioplasties stents 61 myocardial infarction ventricular fibrillation 60 aspirin clopidogrel 60 Val HeFT 60 thromboembolisms 60 mild renal insufficiency 60 Tasigna prolongs 60 esophageal gastric 60 EEG abnormalities 60 unstable angina pectoris 60 thromboembolic complications 60 refractory ischemia 60 silent ischemia 60 anthracycline taxane 60 Percutaneous Transluminal Coronary Angioplasty 60 TAXUS p value 60 dalteparin 60 drotrecogin alfa activated 59 myelodysplastic myeloproliferative diseases 59 fibrinolytic therapy 59 Percutaneous Coronary Intervention 59 TAXUS Express Stent 59 ischemia driven 59 recurrent glioblastoma multiforme 59 shorter telomere length 59 biologic antibody 59 nicardipine 59 NATRECOR R 59 prednisone prednisolone plus 59 recurrent DVT 59 descending thoracic 59 unstable angina UA 59 non splenectomized 59 statistically significant predictor 59 workhorse lesions 59 arterial thromboembolic events 59 DES implantation 59 Angiograms carry slight 59 carotid artery blockage 58 glycoprotein IIb IIIa inhibitors 58 coronary revascularisation 58 revascularized 58 nondiabetic patients 58 atherothrombotic events 58 atherosclerotic renal artery stenosis 58 multivessel disease 58 anticholinergic agents 58 Erythropoietic therapies may 58 venous thromboembolisms 58 beta blockers ACE inhibitors 58 Known hypersensitivity 58 ARCOXIA 58 advanced adenoma 58 colorectal adenoma 58 prospectively stratified 58 ATACAND 58 glycosylated hemoglobin levels 58 tenecteplase 58 antiretroviral naïve 58 sirolimus stent 58 morphometric vertebral fractures 58 mL/min/#.# m 2 58 resuscitated cardiac arrest 58 FUSILEV enhances 58 XIENCE V vs. 58 allogeneic hematopoietic cell 58 CYP#A# substrate 58 glycoprotein IIb IIIa inhibitor 58 GP IIb IIIa inhibitors 57 IIIa inhibitor 57 FFR guided 57 revascularizations 57 reduce serum phosphate 57 hemodynamically significant 57 azilsartan medoxomil 57 NYHA Class II 57 patients undergoing CABG 57 baseline serum creatinine 57 coronary intervention 57 ACTEMRA TM 57 acute STEMI 57 sulfonylurea metformin 57 prospectively defined 57 CALGB # [002] 57 nonfatal myocardial infarction 57 abacavir lamivudine 57 acute myocardial infarctions 57 angina myocardial infarction 57 XIENCE V demonstrated 57 hsCRP levels 57 reinfarction 57 paclitaxel eluting stents 57 underwent balloon angioplasty 57 System IPSS 57 candesartan cilexetil 57 symptomatic hyponatremia 57 BEXXAR Therapeutic Regimen 57 hematopoietic cancers 57 angiotensin converting enzyme inhibitor 57 ICD implantation 57 ARIXTRA 57 dyslipidemia abnormal 57 symptomatic carotid stenosis 57 LV dysfunction 57 antiplatelet medications 57 cardiovascular hospitalizations 57 thrombus aspiration 57 antiplatelet drugs 57 INSPIRE Trial Phase III 57 Mg Usa 57 angioplasty stenting 57 receiving prophylactic anticoagulation 57 approved incretin mimetic 57 achieved ACR# 57 HUNGARY NBH 2 57 trauma malignant tumors 57 lung esophageal 57 reteplase 57 overt hepatic encephalopathy HE 57 generator detaching 57 LVSD 57 ischemic complications 57 thrombotic complications 57 undergoing cardiac catheterization 56 sustained ventricular tachycardia 56 hypertension congestive heart 56 severe hepatic dysfunction 56 STRIDE PD 56 sunitinib Sutent 56 pretransplant 56 observational cohort 56 zoledronic acid Reclast 56 left ventricular systolic 56 microbiologically evaluable 56 β blocker 56 tipranavir ritonavir 56 Avandia Actos 56 saphenous vein graft 56 retinal vein occlusion induced 56 postoperative atrial fibrillation 56 patients receiving myelosuppressive 56 poor metabolizers 56 postintervention 56 intravenous bolus 56 Diamyd r 56 chronic thromboembolic pulmonary 56 elevated transaminases 56 NATRECOR ® 56 non cirrhotic portal 56 moderate immunologic 56 metastatic malignant 56 pooled comparator 56 sell Guidant vascular 56 hepatorenal syndrome 56 achieved CCyR 56 serum phosphorous 56 Achieves Primary Endpoint 56 irbesartan 56 atorvastatin #mg 56 achieved sustained virologic 56 CMV seropositive 56 Atherosclerotic 56 Warfarin Coumadin 56 periprocedural 56 Amgen Neulasta R 56 recurrent VTE 56 carotid artery stenting 56 calcineurin inhibitor 56 unfractionated heparin UFH 56 glulisine 56 polyp recurrence 56 diabetic kidney 56 nonischemic 56 coronary revascularization procedures 56 myocardial infarction MI 56 ug dose 56 bone marrow reticulin deposition 56 anticoagulant warfarin 56 pravastatin Pravachol 56 TAXUS Stent 56 PNH patients 56 Angiographic 56 symptomatic VTE 56 NAVISTAR R 56 Ischemic 56 alpha1 antitrypsin deficiency 56 hypervascular tumors 56 sirolimus eluting 56 renal scarring 56 saline placebo 56 Coronary Artery Bypass Graft 55 HBeAg negative 55 hypertension diabetes mellitus 55 anaphylactic reactions bronchospasm 55 recurrent ischemia 55 adverse cytogenetics 55 lymphomas leukemias 55 ß blockers 55 nadroparin 55 catheter occlusion 55 CYP#A# CYP#D# 55 ventricular tachycardia VT 55 naïve HCV 55 infliximab monotherapy 55 aplastic anemia AA 55 -#.# mm Hg 55 bifurcated lesions 55 alfuzosin 55 beta blocker therapy 55 postoperative AF 55 colon rectal 55 tirofiban 55 carotid angioplasty 55 FluCAM arm 55 cerebral somatic oximeter 55 underwent surgical resection 55 NYHA functional class 55 undergoing peritoneal dialysis 55 heparin induced thrombocytopenia 55 infarction NSTEMI 55 cilostazol 55 apolipoprotein E4 55 ACE inhibitors beta blockers 55 Angiotensin receptor blockers 55 NUCYNTA ™ 55 oral antidiabetes 55 symptomatic intracranial 55 ADCS CGIC 55 mycophenolic acid 55 adenoma recurrence 55 antidepressants fluoxetine 55 undergoing coronary artery 55 SYNTAX trial 55 nevirapine regimen 55 normotensive 55 thrombotic events 55 gestational hypertension 55 death dissection perforation 55 Carotid endarterectomy 55 Navelbine R 55 drug eluting stent implantation 55 vapreotide acetate 55 metastatic GIST 55 Xelox 55 Drug eluting stent 55 elevated fasting glucose 55 β blockers 55 uncoated stent 55 Cardiac Angiography 55 noncardiac 55 nonfatal stroke 55 oral anticoagulation 55 thienopyridine 55 underwent coronary angiography 55 revascularisation 55 glycated hemoglobin HbA1c 55 NNT = 55 pacemakers implantable cardioverter defibrillatorsHELB 55 Intravitreal 55 echocardiographic parameters 55 Secondary endpoints include 55 severe exacerbations 55 bioprosthetic valve 55 Meridia sibutramine 55 metformin sulfonylureas 55 completely resected 55 percutaneous coronary interventions 55 cerebrovascular events 55 salmeterol fluticasone 55 stable angina 55 hemoglobin A1c levels 55 thrombocytopenic 55 Tumor Response 55 Stent thrombosis 55 fibrinolysis 55 Abciximab 55 urgent coronary revascularization 55 #mg sodium #mg [002] 55 prospective observational studies 55 mg QD 55 underwent resection 55 Primary endpoints 55 confirmed CCyR 55 allogeneic HSCT 55 recurrent venous thromboembolism 55 mg kg Hematide 55 Operative mortality 55 preintervention 55 acute myocardial infarction AMI 55 ® lenalidomide 54 recurrent atrial fibrillation 54 circulating EPCs 54 plus GP IIb 54 tamoxifen Nolvadex ® 54 Aceon 54 thoracoscopic lobectomy 54 advanced adenomas 54 Secondary endpoints included 54 venous thromboembolic events 54 systemic embolism 54 certolizumab 54 intima media thickness 54 everolimus eluting stents 54 HIV HCV coinfected 54 Insulin sensitizers 54 transfusion syndrome 54 Radical prostatectomy 54 lipid lowering agents 54 anticlotting drugs 54 acetonide FA 54 CIMZIA ™ 54 mcg kg REBETOL 54 C1 INH deficiency 54 systemic hypotension 54 Atypical Hemolytic Uremic Syndrome 54 decompensated heart failure 54 cancerous colon polyps 54 nucleotide analogue 54 peripheral arterial occlusive disease 54 discontinued Viread 54 #.#/#.# mmHg [001] 54 Mg Uk 54 invasive aspergillosis 54 R entecavir 54 -#.# mg dL [001] 54 revascularization procedure 54 NIASPAN 54 angiotensin converting enzyme inhibitors 54 fasting triglyceride levels 54 anthracycline containing 54 asymptomatic carotid stenosis 54 noninferior 54 underwent CABG 54 revascularization procedures 54 coronary revascularization 54 Adjuvant chemotherapy 54 NMIBC 54 esophageal resection 54 VT VF 54 steroid refractory 54 CABG surgery 54 idraparinux 54 ascending aortic 54 glycosylated hemoglobin HbA1c 54 variant angina 54 myocardial infarction stroke 54 polytherapy 54 nonfasting triglyceride levels 54 treating abdominal aortic 54 Abbott Trilipix 54 Peripheral Arterial 54 Mofenson 54 hormone receptor negative 54 Postoperative complications 54 elevated LDL cholesterol 54 International Prognostic Scoring 54 symptomatic ischemic 54 methotrexate monotherapy 54 carotid endarterectomy CEA 54 TAXUS paclitaxel eluting coronary 54 insulin sensitizing drug 54 Coronary artery bypass grafting 54 advanced hepatocellular carcinoma 54 percutaneous intervention 54 nonfatal MI 54 prespecified secondary 54 carotid intima media 54 IABP 54 nonsignificant difference 54 surgical aortic valve 54 myocardial ischemic events 54 containing abacavir 54 carotid artery stenting CAS 54 kidney allograft 54 inhibit platelet function 54 undergone splenectomy 54 left ventricular dysfunction 54 estimated glomerular filtration 54 R rosiglitazone maleate 54 reintervention 54 Percutaneous Coronary Interventions 54 LNG IUS 54 Colon polyps 54 thyrotoxicosis 54 Coronary artery bypass graft 54 adalimumab Humira 54 8mg/kg 54 plus COPEGUS 54 BoNTA 54 Abbott bioabsorbable everolimus eluting 54 macrovascular events 54 locoregional recurrence 54 Free Survival PFS 54 TAXUS Liberte Long 54 ARCALYST ® 54 nonfatal myocardial infarction MI 54 estramustine 54 heFH 54 KRAS mutant tumors 54 Intra arterial 54 hemoglobin A1c HbA1c 54 acute coronary syndromes ACS 53 Kaplan Meier analysis 53 nondiabetics 53 EmbraceAC 53 QTcF 53 low dose Iluvien 53 4mg/kg 53 incomplete revascularization 53 segment binary restenosis 53 perioperatively 53 aspirin beta blockers 53 EDARBI 53 elevated hsCRP 53 TWYNSTA 53 SIMPADICO 53 ischemic cardiomyopathy 53 prostate carcinogenesis 53 recurrent myocardial infarction 53 glomerular filtration 53 immunosuppressive regimen 53 Related Anemia 53 prostate cancer CaP 53 receiving XGEVA 53 antioxidant supplementation 53 valvular heart disease 53 XIENCE V PROMUS Stent 53 biochemical relapse 53 HBeAg negative patients 53 Myocardial Infarction Study 53 hepatic metastases 53 pyrexia mucositis sepsis febrile 53 oral prednisolone 53 haematologic 53 Cypher Stent 53 Pap smears mammograms 53 mRCC 53 prescribe cholesterol lowering 53 pentostatin 53 TNF blocker therapy 53 prolonged QT interval 53 aneurysms AAA 53 IFN alfa 53 serum estradiol 53 hormonally sensitive 53 plus dexamethasone 53 ExTRACT TIMI 53 symptomatic intracerebral hemorrhage 53 FDA defined valvulopathy 53 postoperative complication 53 ventricular tachyarrhythmia 53 baseline HbA1c 53 Thrombolysis 53 Doxil ® 53 basiliximab 53 postoperative pulmonary 53 confidence interval #.#-#.# 53 preventing restenosis 53 transplantation HCT 53 ® darbepoetin alfa 53 pretreatment serum 53 Nipent R 53 de novo coronary artery 53 lymphocytosis 53 vessel renarrowing 53 pulmonary artery banding 53 mcg QD 53 abnormal lipids 53 binary restenosis 53 cyclophosphamide methotrexate 53 Uncontrolled hypertension 53 reactogenicity 53 endarterectomy 53 Endometrial 53 CrCl 53 recurrent GBM 53 preserved ejection fraction 53 Hypotension 53 salpingo oophorectomy 53 rosuvastatin #mg 53 achieve sustained virologic 53 ventricular dysfunction 53 Losartan 53 ICD implants 53 Hb A1C 53 exocrine pancreatic insufficiency EPI 53 repeat revascularization 53 postoperative delirium 53 HES CEL 53 onset atrial fibrillation 53 asymptomatic PAD 53 colorectal liver metastases 53 paroxysmal AF 53 fluvastatin 53 HepaMate 53 curative surgical resection 53 target lesion revascularizations 53 undergo prostate biopsy 53 hematological parameters 53 liver metastasis 53 Commonly prescribed 53 left ventricular diastolic 53 surgical revascularization 53 anagrelide 53 anticoagulants blood thinners 53 5 Fluorouracil 53 comorbid disorders 53 NSTEMI 53 mg subcutaneous 53 #mg BID [001] 53 mITT population 53 ischemic cardiovascular 53 eplerenone 53 Platinum Chromium 53 TAXUS TM 53 coronary revascularizations 53 nonaspirin 53 antithrombotic therapy 53 TORISEL TM 53 thymectomy 53 FOLFIRI alone 53 ARB telmisartan 53 lovastatin Mevacor 53 retrospective cohort 53 preoperative chemotherapy 53 achieved sustained virological 53 bivalirudin alone 53 perioperative mortality 53 clodronate 53 mg p = 53 Carotid artery 53 HeartMate XVE 53 Thalomid ® 53 progesterone receptor negative 53 atrophic vaginitis 53 factor Xa 53 neutropenic sepsis 53 NSAID associated 53 HOMA IR 53 thromboxane A2 53 glycated hemoglobin levels 53 fatal myocardial infarction 53 diastolic blood pressures 53 Gheorghiade 53 Skin sterol 53 Cystatin C 53 hepatic arterial 53 thrombolytic therapy 53 placebo PBO 53 % CI #.#-#.# [003] 53 asystole 53 6 phosphate dehydrogenase 53 Cypher Sirolimus 53 induced hypoglycemia 53 tumor subtype 53 sirolimus eluting stents 53 receiving INTRON 53 esophagus bladder 53 histologically confirmed 53 posttransplant 53 Spectranetics laser 53 Subgroup analysis 53 Events MACE 53 % CI #.#-#.# [001] 53 Intravitreal injections 53 HbA1C levels 53 xanthine oxidase inhibitor 53 triglyceride concentrations 52 Bextra valdecoxib 52 Myoglobin 52 CHD CVD 52 pancreatic resection 52 warfarin sodium 52 CYPHER Stent 52 anastomotic leak 52 Transcatheter aortic valve implantation 52 atherothrombotic 52 serum GGT 52 receiving SIMPONI 52 dose atorvastatin 52 atheromatous 52 CP CPPS 52 NSTE ACS 52 BrachySil ™ 52 bronchial hyperresponsiveness 52 perinatal morbidity 52 quantitative coronary angiography 52 grade cervical dysplasia 52 HIV uninfected 52 Stage IIIb 52 elevated ALT 52 Fasting glucose 52 P = .# 52 Hazard Ratio 52 hemostatic efficacy 52 obstructive coronary artery 52 Prognostic significance 52 pamidronate 52 WallFlex Biliary RX 52 arteriovenous fistula 52 Vidaza azacitidine 52 stable angina pectoris 52 levosimendan 52 arterial revascularization 52 peripheral artery 52 C Reactive Protein 52 revascularisation procedures 52 cytoreductive nephrectomy 52 lowering homocysteine levels 52 beta estradiol 52 angiographic restenosis 52 retransplantation 52 Menopausal hormone therapy 52 clomipramine 52 paroxysmal atrial fibrillation 52 femoral neck fracture 52 intravesical therapy 52 subconjunctival injection 52 #.#mg/dL 52 nodal metastasis 52 VEGF induced 52 multivariable Cox 52 asymptomatic hyperuricemia 52 atazanavir ritonavir 52 calcium antagonists 52 Vitrasert R 52 pelvic lymphadenectomy 52 LDL cholesterol HDL cholesterol 52 ximelagatran 52 endoscopic remission 52 HIV treatments Reyataz 52 EGFR mutation positive 52 anticoagulated 52 debulking surgery 52 antidiabetic medications 52 intrahepatic 52 cerebrovascular accident 52 prespecified 52 activated partial thromboplastin 52 cystoid macular edema 52 postdischarge 52 desvenlafaxine succinate 52 PRADAXA #mg 52 Postmenopausal hormone therapy 52 Nesiritide 52 Coronary angiography 52 Affiliated Insurers 52 Hazard Ratio = 52 stimulated insulin secretion 52 systemic corticosteroid 52 clopidogrel Plavix 52 multivariate Cox 52 Delayed Graft Function 52 FRAGMIN 52 euthyroid 52 Captopril 52 x ULN 52 MACCE 52 prostate TURP 52 Severity MSCS score 52 bilateral renal artery 52 target lesion revascularization 52 catheter angiography 52 placebo p = 52 sleeve lobectomy 52 carotid revascularization 52 IV tPA 52 oxycodone IR 52 OPCAB 52 sitaxsentan 52 cirrhotic patients 52 neoadjuvant radiation 52 serum creatinine levels 52 mmHg diastolic 52 decompensated cirrhosis 52 mcg BID 52 mmHg p = 52 MELD scores 52 variceal bleeding 52 mediastinitis 52 baseline LDH 52 glucocorticoid induced 52 mg clopidogrel 52 hepatectomy 52 epoetin alpha 52 hemodynamic measurements 52 substantially excreted 52 statistically significant p = 52 Taxus Stent 52 PREVU * LT 52 undetectable HBV DNA 52 autologous SCT 52 systolic dysfunction 52 allogeneic hematopoietic stem cell 52 cardioverter defibrillator 52 arteriography 52 IPAH 52 BRCA1 mutation carriers 52 Echocardiographic 52 intravascular ultrasonography 52 Zevalin consolidation 52 inhaled glucocorticoids 52 distal colon cancer 52 potassium sparing 52 cystoscopic 52 T1c 52 immune suppressing medication 52 attain statistical significance 52 clot busting therapy 52 lowest tertile 52 bronchopulmonary dysplasia BPD 52 abnormal lipid 52 abdominal aortic aneurysms AAA 52 5-FU/LV 52 resynchronization therapy 52 recurrent ischemic 52 removed laparoscopically 52 LMWH 52 % CI #.#-#.# [008] 52 eluting stent 52 SSc 52 HF hospitalization 52 cardiac resynchronization 52 XZK 52 #:#-# [031] 52 atherothrombotic disease 52 cardiopulmonary diseases 52 KIF6 carriers 52 human Chorionic Gonadotropin 52 cardiac repolarization 52 elective PCI 52 percutaneous interventions 52 ventricular fibrillation VF 52 stratifying patients 52 CCyR 52 diuretics beta blockers 52 response CCyR 52 occlusive disease 52 intracerebral hemorrhage 52 antiplatelet agent 52 myocardial infarctions MIs 52 cerebral oxygenation 52 Papillary 52 cTnI 52 leptin deficiency 52 USPSTF recommends 52 PSA nadir 52 mCi kg 52 noncardiovascular mortality 52 intracranial stenosis 52 dual endothelin receptor antagonist 52 VKORC1 52 CYP#D# genotype 52 events MACE 52 stenting procedures 52 daily subcutaneous injections 52 impaired insulin secretion 52 Nonsurgical 52 allogeneic transplants 52 defibrillator CRT D 52 thrombectomy 52 fludarabine cyclophosphamide 52 adjuvant radiotherapy 52 peripheral arterial 52 Paliperidone ER 52 oxycodone CR 52 thyrotropin levels 52 CTEPH 52 UA NSTEMI 52 tumor progression TTP 52 cerebrovascular accidents 52 cytotoxic therapy 52 coronary stenosis 52 serum biomarker 52 combination estrogen progestin 52 IOP lowering 52 administering VIVITROL 51 myeloid metaplasia 51 urgent revascularization 51 symptomatic DVT 51 relapsed refractory multiple myeloma 51 undergoing CABG 51 ZOLINZA 51 pyelonephritis 51 neointimal 51 mCRPC 51 undergoing elective 51 tolterodine ER 51 histologic subtype 51 nonobstructive 51 artery stenosis 51 Ovary removal 51 Castration Resistant Prostate Cancer 51 metformin monotherapy 51 intestinal mucosal 51 ezetimibe simvastatin 51 meta analytic review 51 preterm newborns 51 sternal wound infections 51 proximal DVT 51 bone marrow reticulin 51 neovascularisation 51 Pneumococcal vaccination 51 prescribed antipsychotic medication 51 Fasting blood glucose 51 confidence interval CI 51 anthracycline unless 51 highest tertile 51 comorbid illnesses 51 prophylactic cranial irradiation 51 ticlopidine 51 curative resection 51 pulmonary alveolar 51 elevated triglyceride levels 51 urinary cortisol 51 ribavirin therapy 51 platelet aggregation inhibitor 51 hypertension hypercholesterolemia 51 Altera Nebulizer System 51 angiographic outcomes 51 prolongs survival 51 CIN2 + 51 revealed multivessel coronary 51 droperidol 51 CI #.#-#.# [002] 51 neutropenia dehydration dyspnea 51 calculated creatinine clearance 51 DAPT 51 inhospital 51 HPV vaccine GlaxoSmithKline Cervarix 51 comparator arm 51 unfractionated heparin 51 metformin accumulation 51 treat atrial flutter 51 CI #.#-#.# [001] 51 mg ustekinumab 51 % CI #.#-#.# [005] 51 ipsilateral stroke 51 radical retropubic prostatectomy 51 Therein lurks 51 de novo lesions 51 thromboprophylaxis 51 Manobo tribal elders 51 stent binary restenosis 51 thrombo embolic 51 percutaneous catheter 51 concurrent chemoradiation 51 TURBT 51 cromolyn sodium 51 HBeAg seroconversion 51 mg BID dose 51 Flovent HFA 51 artery reclogging 51 ACEI ARB 51 Angiotensin converting enzyme 51 statins cholesterol lowering 51 target vessel revascularization 51 stage IIIA 51 serum urate 51 allogenic stem cell 51 meta regression 51 Coronary stent 51 intracerebral hemorrhage ICH 51 obstructive coronary 51 VcMP 51 Bibbins Domingo 51 Levaquin levofloxacin 51 upper gastrointestinal bleeding 51 Darapladib 51 TNF antagonist 51 genitourinary GU 51 peri procedural 51 carotid artery intima media 51 pulsatility index 51 deCODE Glaucoma TM 51 asymptomatic bacteriuria 51 dobutamine 51 LDL triglycerides 51 concomitant antibiotics 51 RAS blockers 51 Median progression 51 creatine kinase MB 51 QTc intervals 51 sumatriptan naproxen sodium 51 cervical cerclage 51 postoperative mortality 51 Hp2 2 51 DAS# CRP 51 serum phosphate 51 chemoradiation therapy 51 CC genotype 51 complete cytogenetic response 51 ADAS Cog 51 intra arterial 51 acute coronary syndrome 51 lispro 51 -#.# mg dL [002] 51 contralateral breast 51 rate CZECH NATIONAL 51 coronary stenting 51 carotid bruit 51 rt PA 51 KIF6 gene variant 51 parkinsonian symptoms 51 hemoglobin A1C HbA1C 51 invasive lobular 51 Prostate specific antigen 51 initiating antiretroviral therapy 51 cystic fibrosis chronic pancreatitis 51 Median PFS 51 subclinical atherosclerosis 51 Cardiopulmonary bypass 51 antibody titer 51 Zenapax 51 Eluting Coronary Stent System 51 aspartate aminotransferase AST 51 bezafibrate 51 Sentinel Lymph Node Biopsy 51 hepatic liver 51 mg d 51 Severe hypoglycemia 51 thromboembolic events 51 vecuronium 51 intracerebral haemorrhage 51 distal embolization thrombus formation 51 tachyarrhythmias 51 subthalamic 51 Persistent Sleep 51 KRAS mutations occur 51 Actos pioglitazone 51 liver resection surgeries 51 Major Adverse Cardiac 51 enoxaparin sodium 51 coronary vascular 51 stent thromboses 51 polyarticular 51 systolic function 51 intracavitary 51 Secondary efficacy endpoints 51 edifoligide 51 coronary interventions 51 Fasting plasma glucose 51 Myocardial infarction 51 nonobstructive CAD 51 valvular disease 51 pretest probability 51 Tranexamic acid 51 active comparator 51 TIMP 1 51 Septal 51 postoperative chemotherapy 51 Kaplan Meier estimates 51 transferrin saturation 51 CentriMag 51 pCR 51 undergoing angioplasty 51 Fanconi syndrome 51 HBeAg positive patients 51 Tambocor 51 BRCA2 mutation carriers 51 lumen diameter 51 Flu Cy 51 thromboembolic diseases 51 aldosterone antagonist 51 INVEGA ™ 51 Airway Bypass 51 prescribed statins 51 Sandimmune 51 embolic stroke 51 ventricular septum 51 Levacor TM 51 adenovirus mediated 51 abnormal lipid levels 51 intracoronary 51 perioperative complications 51 thromboembolic 51 #mg QD [002] 51 Coherex FlatStent 51 functional mitral regurgitation 51 silent myocardial ischemia 51 Aprotinin 51 rFVIIa